Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...
CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Pfizer ( PFE 3.18%) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback